Why is “choice” in matters of one’s personal health suddenly a bad thing?
NYS Entity Status
NYS Filing Date
MAY 10, 2013
NYS DOS ID#
ONE COMMERCE PLAZA,
99 WASHINGTON AVENUE #805A
ALBANY, NEW YORK, 12210-2822
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - FRINGE INSURANCE AGENCY BENEFITS
2013 - FRINGE INSURANCE BENEFITS, INC.
AROUND THE WEB
- 'Junk Insurance' vs. 'Junk News' at the NY Times
Monday Jul 17, 2017
- NY insurance company dragged into Wells Fargo scandal
By Kevin Dugan - Tuesday Aug 1, 2017
The New York insurance company that wrote policies for 800,000 questionable Wells Fargo auto loans has been dragged into the bank’s latest scandal. National General Insurance was named in a class-action lawsuit filed against the bank — for allegedly unduly profiting from $80 million in collateral protection insurance that the drivers didn’t need — and...
- With Health Law in Flux, Insurers Scramble to Meet Filing Deadline
By REED ABELSON - Wednesday Jun 21, 2017
Anthem, a major player in the Obamacare exchanges, announced that it would withdraw from Wisconsin and Indiana next year, along with Ohio.
- Anthem Says Senate Health Bill Will Bolster Individual Insurance Market
Monday Jun 26, 2017
Anthem Inc. said it believes that the Senate Republicans’ health bill will bolster the individual insurance market, an endorsement for the legislation as many other insurers have suggested it could undermine the marketplaces created by the Affordable Care Act.
- Restaurant Review: Vegetables With Benefits at ABCV
By PETE WELLS - Monday Jul 3, 2017
The menu at Jean-Georges Vongerichten’s new vegetarian restaurant in the Flatiron district tries to impart “plant-based intelligence.”
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.